Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Veterans | 31 | 2024 | 2519 | 2.220 |
Why?
|
Veterans Health | 4 | 2024 | 216 | 0.960 |
Why?
|
Technology | 1 | 2024 | 304 | 0.790 |
Why?
|
Chlorthalidone | 3 | 2022 | 19 | 0.580 |
Why?
|
Antirheumatic Agents | 7 | 2023 | 1338 | 0.570 |
Why?
|
United States Department of Veterans Affairs | 13 | 2022 | 875 | 0.540 |
Why?
|
Medical Oncology | 5 | 2024 | 2267 | 0.490 |
Why?
|
Sulfasalazine | 3 | 2017 | 79 | 0.410 |
Why?
|
Hydrochlorothiazide | 3 | 2022 | 98 | 0.410 |
Why?
|
Arthritis, Rheumatoid | 7 | 2023 | 3712 | 0.380 |
Why?
|
Allopurinol | 2 | 2023 | 191 | 0.360 |
Why?
|
Multiple Myeloma | 7 | 2023 | 5181 | 0.350 |
Why?
|
Venous Thromboembolism | 4 | 2023 | 1671 | 0.350 |
Why?
|
Workflow | 4 | 2024 | 847 | 0.350 |
Why?
|
Hydroxychloroquine | 3 | 2017 | 412 | 0.310 |
Why?
|
Diuretics | 4 | 2023 | 591 | 0.310 |
Why?
|
Neoplasms | 9 | 2024 | 21696 | 0.300 |
Why?
|
Lung Neoplasms | 6 | 2024 | 13104 | 0.290 |
Why?
|
Methotrexate | 4 | 2017 | 1728 | 0.280 |
Why?
|
Databases, Factual | 3 | 2019 | 7730 | 0.280 |
Why?
|
Gout | 2 | 2023 | 573 | 0.240 |
Why?
|
United States | 36 | 2024 | 69872 | 0.240 |
Why?
|
Warfarin | 3 | 2004 | 1497 | 0.230 |
Why?
|
Drug Hypersensitivity | 2 | 2003 | 884 | 0.230 |
Why?
|
Thromboplastin | 2 | 1994 | 291 | 0.200 |
Why?
|
Spondylitis, Ankylosing | 1 | 2023 | 156 | 0.200 |
Why?
|
Lisinopril | 2 | 2013 | 54 | 0.200 |
Why?
|
Simvastatin | 2 | 2008 | 360 | 0.200 |
Why?
|
Aphasia | 1 | 2003 | 184 | 0.200 |
Why?
|
Disulfiram | 1 | 2021 | 57 | 0.200 |
Why?
|
Hematologic Neoplasms | 2 | 2024 | 1832 | 0.200 |
Why?
|
Humans | 88 | 2024 | 744366 | 0.190 |
Why?
|
Patient Identification Systems | 1 | 2020 | 79 | 0.180 |
Why?
|
Anticoagulants | 6 | 2020 | 4600 | 0.180 |
Why?
|
Eligibility Determination | 1 | 2024 | 403 | 0.180 |
Why?
|
Sodium Bicarbonate | 2 | 2017 | 62 | 0.180 |
Why?
|
Paraproteinemias | 1 | 2022 | 246 | 0.180 |
Why?
|
Losartan | 2 | 2013 | 299 | 0.170 |
Why?
|
Gulf War | 1 | 2018 | 29 | 0.170 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2024 | 5223 | 0.170 |
Why?
|
Histiocytosis, Langerhans-Cell | 1 | 2000 | 171 | 0.170 |
Why?
|
Vitamin K | 1 | 2001 | 295 | 0.160 |
Why?
|
Acute Kidney Injury | 3 | 2017 | 1968 | 0.160 |
Why?
|
Ecosystem | 1 | 2023 | 474 | 0.160 |
Why?
|
Acetylcysteine | 2 | 2017 | 271 | 0.160 |
Why?
|
Hypolipidemic Agents | 1 | 2003 | 604 | 0.160 |
Why?
|
Hiccup | 1 | 1998 | 9 | 0.160 |
Why?
|
Dexamethasone | 3 | 2023 | 1951 | 0.160 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 2 | 2013 | 451 | 0.160 |
Why?
|
Natural Language Processing | 2 | 2023 | 1041 | 0.160 |
Why?
|
Antiviral Agents | 4 | 2024 | 2987 | 0.160 |
Why?
|
Chromatography, Liquid | 1 | 2021 | 976 | 0.150 |
Why?
|
Drug Dosage Calculations | 1 | 2018 | 114 | 0.150 |
Why?
|
Biological Products | 2 | 2017 | 860 | 0.150 |
Why?
|
Computer Security | 1 | 2019 | 262 | 0.150 |
Why?
|
Prothrombin Time | 2 | 1994 | 119 | 0.150 |
Why?
|
Bipolar Disorder | 3 | 2021 | 5027 | 0.150 |
Why?
|
Specimen Handling | 1 | 2021 | 694 | 0.140 |
Why?
|
Medical Informatics | 1 | 2024 | 745 | 0.140 |
Why?
|
Aged | 31 | 2024 | 163288 | 0.140 |
Why?
|
Research Design | 8 | 2023 | 5984 | 0.140 |
Why?
|
Hypertension | 3 | 2022 | 8479 | 0.140 |
Why?
|
Point-of-Care Systems | 3 | 2023 | 1178 | 0.140 |
Why?
|
Prostatectomy | 2 | 2020 | 1890 | 0.140 |
Why?
|
Patient Care Management | 1 | 2019 | 306 | 0.140 |
Why?
|
Biological Factors | 1 | 2017 | 164 | 0.140 |
Why?
|
Virus Diseases | 1 | 2022 | 711 | 0.140 |
Why?
|
Medical Order Entry Systems | 2 | 2012 | 545 | 0.130 |
Why?
|
International Classification of Diseases | 1 | 2021 | 867 | 0.130 |
Why?
|
Schizophrenia | 3 | 2021 | 6882 | 0.130 |
Why?
|
Psoriasis | 1 | 2023 | 902 | 0.130 |
Why?
|
Sodium Chloride | 1 | 2017 | 625 | 0.130 |
Why?
|
Sucrose | 1 | 1995 | 164 | 0.130 |
Why?
|
Meningioma | 1 | 2024 | 1209 | 0.130 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2016 | 9955 | 0.130 |
Why?
|
Drug Therapy, Combination | 10 | 2017 | 6489 | 0.130 |
Why?
|
Antihypertensive Agents | 3 | 2022 | 2047 | 0.130 |
Why?
|
Meningeal Neoplasms | 1 | 2024 | 1241 | 0.120 |
Why?
|
Clinical Trials as Topic | 3 | 2019 | 7914 | 0.120 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2013 | 1516 | 0.120 |
Why?
|
Angiography | 2 | 2017 | 1639 | 0.120 |
Why?
|
Mass Spectrometry | 1 | 2021 | 2204 | 0.120 |
Why?
|
Diabetic Nephropathies | 2 | 2013 | 984 | 0.120 |
Why?
|
Learning | 1 | 2024 | 1711 | 0.120 |
Why?
|
Occupational Health | 1 | 2020 | 808 | 0.120 |
Why?
|
Anaphylaxis | 1 | 2001 | 746 | 0.120 |
Why?
|
Male | 40 | 2024 | 350115 | 0.110 |
Why?
|
Epidemiologic Methods | 1 | 2018 | 1364 | 0.110 |
Why?
|
Venous Thrombosis | 1 | 2023 | 1239 | 0.110 |
Why?
|
Hospitals, Veterans | 4 | 2022 | 404 | 0.110 |
Why?
|
Melanoma | 2 | 2022 | 5511 | 0.110 |
Why?
|
Genome-Wide Association Study | 3 | 2021 | 12262 | 0.110 |
Why?
|
Prostatic Neoplasms | 4 | 2024 | 11126 | 0.110 |
Why?
|
Hodgkin Disease | 1 | 2000 | 1415 | 0.110 |
Why?
|
Middle Aged | 29 | 2024 | 213390 | 0.110 |
Why?
|
Contrast Media | 2 | 2017 | 5300 | 0.100 |
Why?
|
Anti-Inflammatory Agents | 1 | 2022 | 1790 | 0.100 |
Why?
|
Proteome | 1 | 2021 | 1798 | 0.100 |
Why?
|
Research Support as Topic | 1 | 2015 | 705 | 0.100 |
Why?
|
Immunoglobulins, Intravenous | 1 | 1995 | 652 | 0.100 |
Why?
|
Retrospective Studies | 14 | 2024 | 77460 | 0.100 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2013 | 595 | 0.090 |
Why?
|
Disability Evaluation | 2 | 2017 | 1828 | 0.090 |
Why?
|
Vitamin D Deficiency | 1 | 2020 | 1343 | 0.090 |
Why?
|
Biological Specimen Banks | 1 | 2015 | 711 | 0.090 |
Why?
|
Software | 2 | 2023 | 4441 | 0.090 |
Why?
|
Pulmonary Embolism | 1 | 2023 | 2375 | 0.090 |
Why?
|
Cohort Studies | 9 | 2023 | 40559 | 0.090 |
Why?
|
Gout Suppressants | 2 | 2023 | 166 | 0.090 |
Why?
|
Plasma Cells | 2 | 2023 | 591 | 0.090 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 1998 | 1524 | 0.090 |
Why?
|
Peptides | 1 | 2021 | 4410 | 0.090 |
Why?
|
Double-Blind Method | 7 | 2018 | 12025 | 0.080 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2023 | 2428 | 0.080 |
Why?
|
Thrombosis | 1 | 2023 | 2968 | 0.080 |
Why?
|
Algorithms | 3 | 2024 | 13882 | 0.080 |
Why?
|
Electronic Health Records | 6 | 2023 | 4468 | 0.080 |
Why?
|
Glioblastoma | 1 | 2024 | 3481 | 0.080 |
Why?
|
Information Dissemination | 1 | 2017 | 1099 | 0.080 |
Why?
|
Frail Elderly | 2 | 2023 | 693 | 0.080 |
Why?
|
Gastrointestinal Diseases | 1 | 2017 | 1170 | 0.080 |
Why?
|
Proteomics | 1 | 2021 | 3638 | 0.080 |
Why?
|
Risk Factors | 11 | 2023 | 72296 | 0.080 |
Why?
|
Aged, 80 and over | 11 | 2023 | 57776 | 0.080 |
Why?
|
Glucocorticoids | 1 | 1998 | 2108 | 0.080 |
Why?
|
Pilot Projects | 2 | 2019 | 8319 | 0.080 |
Why?
|
Female | 29 | 2024 | 380193 | 0.080 |
Why?
|
Occupational Exposure | 1 | 2018 | 1793 | 0.080 |
Why?
|
Drug Costs | 1 | 2015 | 1105 | 0.080 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 3524 | 0.080 |
Why?
|
Medical Records | 2 | 2023 | 1413 | 0.070 |
Why?
|
Cost-Benefit Analysis | 2 | 2017 | 5388 | 0.070 |
Why?
|
Dementia | 1 | 2021 | 2518 | 0.070 |
Why?
|
Health Status Disparities | 1 | 2019 | 1796 | 0.070 |
Why?
|
Health Personnel | 1 | 2020 | 3219 | 0.070 |
Why?
|
Cooperative Behavior | 1 | 2014 | 1504 | 0.070 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 3086 | 0.070 |
Why?
|
Insulin | 2 | 2012 | 6582 | 0.070 |
Why?
|
Vaccination | 3 | 2023 | 3279 | 0.070 |
Why?
|
Proteinuria | 1 | 2008 | 658 | 0.070 |
Why?
|
Adult | 17 | 2024 | 214052 | 0.070 |
Why?
|
Atrial Fibrillation | 1 | 2004 | 5035 | 0.070 |
Why?
|
Monitoring, Physiologic | 1 | 1993 | 1739 | 0.070 |
Why?
|
Pancreatic Neoplasms | 1 | 2023 | 5263 | 0.060 |
Why?
|
Uric Acid | 2 | 2023 | 766 | 0.060 |
Why?
|
Alanine Transaminase | 1 | 2008 | 592 | 0.060 |
Why?
|
Cognition Disorders | 1 | 2019 | 4043 | 0.060 |
Why?
|
Health Status | 1 | 2018 | 4034 | 0.060 |
Why?
|
Taxoids | 1 | 2008 | 666 | 0.060 |
Why?
|
Antineoplastic Agents | 2 | 2023 | 13693 | 0.060 |
Why?
|
Incidence | 5 | 2023 | 20952 | 0.060 |
Why?
|
Treatment Outcome | 11 | 2023 | 63107 | 0.060 |
Why?
|
Genomics | 2 | 2017 | 5717 | 0.060 |
Why?
|
Sodium Chloride Symporter Inhibitors | 1 | 2022 | 76 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2024 | 8861 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3135 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3242 | 0.050 |
Why?
|
Polypharmacy | 1 | 2005 | 294 | 0.050 |
Why?
|
Knowledge | 1 | 2024 | 181 | 0.050 |
Why?
|
Cognition | 1 | 2019 | 6770 | 0.050 |
Why?
|
Hyperglycemia | 1 | 2011 | 1373 | 0.050 |
Why?
|
Fatty Liver | 1 | 2008 | 727 | 0.050 |
Why?
|
Tissue Banks | 1 | 2002 | 184 | 0.050 |
Why?
|
Vitamin K Deficiency | 1 | 2001 | 24 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2021 | 5692 | 0.050 |
Why?
|
Genotype | 4 | 2020 | 12952 | 0.050 |
Why?
|
Immunoglobulin G | 1 | 2013 | 4561 | 0.050 |
Why?
|
Drug Administration Routes | 1 | 2001 | 153 | 0.050 |
Why?
|
Prognosis | 4 | 2023 | 29060 | 0.050 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2001 | 188 | 0.050 |
Why?
|
Delivery of Health Care | 3 | 2023 | 5321 | 0.050 |
Why?
|
Kidney Failure, Chronic | 2 | 2013 | 2535 | 0.050 |
Why?
|
Jurkat Cells | 1 | 2021 | 743 | 0.040 |
Why?
|
Drug Monitoring | 2 | 2018 | 956 | 0.040 |
Why?
|
Reference Standards | 2 | 1994 | 1025 | 0.040 |
Why?
|
Administration, Oral | 3 | 2017 | 3914 | 0.040 |
Why?
|
Systems Integration | 1 | 2020 | 440 | 0.040 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2019 | 288 | 0.040 |
Why?
|
Comorbidity | 2 | 2021 | 10388 | 0.040 |
Why?
|
Goals | 1 | 2023 | 707 | 0.040 |
Why?
|
Metoclopramide | 1 | 1998 | 51 | 0.040 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 253 | 0.040 |
Why?
|
Attitude | 1 | 2023 | 776 | 0.040 |
Why?
|
Length of Stay | 1 | 2011 | 6311 | 0.040 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2001 | 469 | 0.040 |
Why?
|
Ambulatory Care Facilities | 1 | 2024 | 934 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2018 | 10943 | 0.040 |
Why?
|
Quality Control | 1 | 2020 | 841 | 0.040 |
Why?
|
Blood Specimen Collection | 1 | 2018 | 246 | 0.040 |
Why?
|
Ileus | 1 | 2017 | 58 | 0.040 |
Why?
|
Medication Therapy Management | 1 | 2018 | 127 | 0.040 |
Why?
|
Life Tables | 1 | 2017 | 370 | 0.040 |
Why?
|
SEER Program | 1 | 2022 | 1507 | 0.040 |
Why?
|
Dopamine Antagonists | 1 | 1998 | 296 | 0.040 |
Why?
|
Hemoglobins | 1 | 2023 | 1532 | 0.040 |
Why?
|
Vasodilation | 1 | 2001 | 944 | 0.040 |
Why?
|
Ethics, Medical | 1 | 2002 | 792 | 0.040 |
Why?
|
Blood Pressure | 2 | 2022 | 8551 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2020 | 3480 | 0.040 |
Why?
|
Drug Interactions | 1 | 2001 | 1460 | 0.030 |
Why?
|
Comparative Effectiveness Research | 2 | 2012 | 680 | 0.030 |
Why?
|
Gingival Hemorrhage | 1 | 1995 | 49 | 0.030 |
Why?
|
Prospective Studies | 5 | 2023 | 53290 | 0.030 |
Why?
|
Geriatric Assessment | 1 | 2023 | 1372 | 0.030 |
Why?
|
Registries | 2 | 2022 | 8091 | 0.030 |
Why?
|
Informed Consent | 1 | 2002 | 995 | 0.030 |
Why?
|
Drug Prescriptions | 1 | 2005 | 1637 | 0.030 |
Why?
|
HeLa Cells | 1 | 2021 | 3130 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2023 | 1070 | 0.030 |
Why?
|
Aspirin | 2 | 2002 | 3283 | 0.030 |
Why?
|
Gastritis | 1 | 2017 | 196 | 0.030 |
Why?
|
Time Factors | 4 | 2021 | 40075 | 0.030 |
Why?
|
Sequence Analysis | 1 | 2015 | 256 | 0.030 |
Why?
|
Tumor Burden | 1 | 2021 | 1915 | 0.030 |
Why?
|
Drug Substitution | 1 | 2017 | 281 | 0.030 |
Why?
|
Propensity Score | 1 | 2021 | 1781 | 0.030 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2001 | 691 | 0.030 |
Why?
|
Renal Dialysis | 2 | 2017 | 1783 | 0.030 |
Why?
|
Medicare | 2 | 2023 | 6566 | 0.030 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2008 | 11726 | 0.030 |
Why?
|
Neuropsychological Tests | 2 | 2019 | 6994 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2021 | 12356 | 0.030 |
Why?
|
Blotting, Western | 1 | 2021 | 5181 | 0.030 |
Why?
|
Patient Care | 1 | 2019 | 640 | 0.030 |
Why?
|
Glomerular Filtration Rate | 2 | 2013 | 2166 | 0.030 |
Why?
|
Genetic Markers | 1 | 2020 | 2634 | 0.030 |
Why?
|
Fluid Therapy | 1 | 2017 | 593 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2012 | 5749 | 0.030 |
Why?
|
Antibodies | 1 | 2021 | 2460 | 0.030 |
Why?
|
Abscess | 1 | 2017 | 607 | 0.030 |
Why?
|
Intestinal Obstruction | 1 | 2017 | 423 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2001 | 1584 | 0.030 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 3255 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2017 | 2274 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2021 | 3616 | 0.030 |
Why?
|
Risk Assessment | 4 | 2023 | 23336 | 0.030 |
Why?
|
Hemorrhage | 2 | 2002 | 3461 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2021 | 19905 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2014 | 17446 | 0.030 |
Why?
|
Free Radical Scavengers | 1 | 2013 | 216 | 0.030 |
Why?
|
Creatinine | 1 | 2017 | 1919 | 0.030 |
Why?
|
Quality of Life | 2 | 2023 | 12802 | 0.030 |
Why?
|
Canada | 1 | 2017 | 2065 | 0.030 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2023 | 4424 | 0.030 |
Why?
|
Remission Induction | 1 | 2017 | 2385 | 0.030 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2002 | 2282 | 0.030 |
Why?
|
ROC Curve | 1 | 2019 | 3528 | 0.030 |
Why?
|
DNA, Neoplasm | 1 | 2017 | 1758 | 0.020 |
Why?
|
Pandemics | 2 | 2023 | 8385 | 0.020 |
Why?
|
Disease Outbreaks | 1 | 2020 | 1771 | 0.020 |
Why?
|
Inpatients | 1 | 2023 | 2518 | 0.020 |
Why?
|
Longitudinal Studies | 2 | 2018 | 13991 | 0.020 |
Why?
|
Alcoholism | 1 | 2021 | 1906 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2019 | 3921 | 0.020 |
Why?
|
Bleeding Time | 1 | 1990 | 89 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2022 | 2569 | 0.020 |
Why?
|
Oxygen | 1 | 2022 | 4189 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2017 | 1683 | 0.020 |
Why?
|
Urinary Tract Infections | 1 | 2017 | 788 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2020 | 15520 | 0.020 |
Why?
|
Cost Savings | 1 | 2015 | 925 | 0.020 |
Why?
|
Body Mass Index | 1 | 2008 | 12721 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2021 | 15535 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2023 | 2213 | 0.020 |
Why?
|
Pancreatitis | 1 | 2017 | 1092 | 0.020 |
Why?
|
Drug Industry | 1 | 2015 | 746 | 0.020 |
Why?
|
Respiratory Tract Infections | 1 | 2017 | 961 | 0.020 |
Why?
|
Demography | 1 | 2014 | 1655 | 0.020 |
Why?
|
Follow-Up Studies | 3 | 2019 | 39052 | 0.020 |
Why?
|
Platelet Function Tests | 1 | 1990 | 270 | 0.020 |
Why?
|
Genome, Human | 1 | 2002 | 4420 | 0.020 |
Why?
|
Postoperative Care | 1 | 1995 | 1487 | 0.020 |
Why?
|
Alleles | 1 | 2019 | 6933 | 0.020 |
Why?
|
Health Surveys | 1 | 2018 | 4036 | 0.020 |
Why?
|
Mortality | 1 | 2019 | 2864 | 0.020 |
Why?
|
Lovastatin | 1 | 2008 | 120 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9312 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2618 | 0.020 |
Why?
|
Health Behavior | 1 | 2018 | 2635 | 0.020 |
Why?
|
Hyperkalemia | 1 | 2008 | 218 | 0.020 |
Why?
|
Linear Models | 1 | 2017 | 5953 | 0.020 |
Why?
|
Heart Valve Prosthesis | 1 | 1995 | 1490 | 0.020 |
Why?
|
International Cooperation | 1 | 1993 | 1420 | 0.020 |
Why?
|
Data Collection | 1 | 2015 | 3339 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2024 | 21748 | 0.020 |
Why?
|
Pravastatin | 1 | 2008 | 395 | 0.020 |
Why?
|
Medical Records Systems, Computerized | 1 | 2012 | 1205 | 0.020 |
Why?
|
Obesity | 1 | 2008 | 12746 | 0.020 |
Why?
|
Adolescent | 2 | 2024 | 85779 | 0.020 |
Why?
|
Pneumonia | 1 | 2017 | 2133 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2021 | 16690 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 7785 | 0.020 |
Why?
|
Young Adult | 2 | 2024 | 56429 | 0.020 |
Why?
|
Quality Improvement | 1 | 2019 | 3749 | 0.020 |
Why?
|
Prevalence | 1 | 2021 | 15221 | 0.020 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2008 | 841 | 0.010 |
Why?
|
Environmental Exposure | 1 | 2018 | 4232 | 0.010 |
Why?
|
Bayes Theorem | 1 | 2012 | 2307 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2015 | 3611 | 0.010 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2017 | 2200 | 0.010 |
Why?
|
Regression Analysis | 1 | 1993 | 6459 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 6539 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 11525 | 0.010 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 1995 | 3070 | 0.010 |
Why?
|
Hospitalization | 1 | 2022 | 10259 | 0.010 |
Why?
|
Age Distribution | 1 | 2008 | 2902 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5135 | 0.010 |
Why?
|
Sensitivity and Specificity | 2 | 1995 | 14723 | 0.010 |
Why?
|
Radiotherapy | 1 | 2008 | 1533 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7282 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2002 | 11718 | 0.010 |
Why?
|
Phlebotomy | 1 | 2001 | 141 | 0.010 |
Why?
|
Anticholesteremic Agents | 1 | 2008 | 979 | 0.010 |
Why?
|
Odds Ratio | 2 | 2008 | 9849 | 0.010 |
Why?
|
International Normalized Ratio | 1 | 2002 | 367 | 0.010 |
Why?
|
Outpatients | 1 | 2008 | 1487 | 0.010 |
Why?
|
Body Weight | 1 | 2011 | 4671 | 0.010 |
Why?
|
Hemoptysis | 1 | 2001 | 155 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2020 | 6773 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 25039 | 0.010 |
Why?
|
Patient Selection | 1 | 2012 | 4216 | 0.010 |
Why?
|
Mutation | 1 | 2024 | 29786 | 0.010 |
Why?
|
Terminology as Topic | 1 | 2005 | 1547 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2008 | 6896 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 15160 | 0.010 |
Why?
|
Radiography | 1 | 2008 | 7023 | 0.010 |
Why?
|
Hematoma | 1 | 2001 | 758 | 0.010 |
Why?
|
Recurrence | 1 | 2008 | 8340 | 0.010 |
Why?
|
Risk | 1 | 2008 | 9688 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2008 | 12244 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 2008 | 4251 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2020 | 20824 | 0.010 |
Why?
|
Disease Progression | 1 | 2008 | 13286 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2008 | 15078 | 0.010 |
Why?
|
Safety | 1 | 1995 | 1186 | 0.010 |
Why?
|
Confidence Intervals | 1 | 1995 | 2971 | 0.010 |
Why?
|
Blood Coagulation Tests | 1 | 1990 | 263 | 0.010 |
Why?
|
Animals | 1 | 2001 | 168768 | 0.010 |
Why?
|
Survival Rate | 1 | 2002 | 12788 | 0.000 |
Why?
|
Platelet Aggregation | 1 | 1990 | 798 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 1 | 2001 | 20130 | 0.000 |
Why?
|